Moderna (NASDAQ: MRNA) recently received a number of ratings updates from brokerages and research firms:
- 10/9/2026 – Moderna had its price target raised by Bank of America Corporation from $170.00 to $200.00. They now have a “neutral” rating on the stock.
- 10/8/2026 – Moderna had its price target raised by Evercore Inc from $50.00 to $80.00.
- 10/7/2026 – Moderna had its price target raised by Morgan Stanley from $89.00 to $95.00. They now have an “equal weight” rating on the stock.
- 9/30/2026 – Moderna was downgraded by Citigroup Inc. from “neutral” to “sell”. They now have a $80.00 price target on the stock, up from $60.00.
- 9/25/2026 – Moderna had its “market perform” rating reaffirmed by Sanford C. Bernstein.
- 9/23/2026 – Moderna was upgraded by Singular Research to “hold”.
- 9/22/2026 – Moderna had its “neutral” rating reaffirmed by UBS Group AG.
- 9/11/2026 – Moderna had its price target raised by Berenberg Bank from $45.00 to $100.00. They now have a “hold” rating on the stock.
- 9/9/2026 – Moderna had its “sell (d-)” rating reaffirmed by Weiss Ratings.
- 9/3/2026 – Moderna was given a new $81.00 price target by UBS Group AG.
- 9/3/2026 – Moderna was downgraded by UBS Group AG from “hold” to “sell”.
- 9/3/2026 – Moderna was downgraded by Rothschild & Co Redburn from “neutral” to “sell”. They now have a $81.00 price target on the stock, up from $40.00.
- 8/28/2026 – Moderna was upgraded by CLSA to “outperform”.
- 8/28/2026 – Moderna is now covered by Deutsche Bank Aktiengesellschaft. They set a “hold” rating and a $125.00 price target on the stock.
- 8/28/2026 – Moderna is now covered by William Blair. They set an “outperform” rating on the stock.
- 8/28/2026 – Moderna was upgraded by Bradesco Corretora to “outperform”.
- 8/28/2026 – Moderna was upgraded by Argus from “hold” to “buy”. They now have a $180.00 price target on the stock.
- 8/25/2026 – Moderna was upgraded by Wolfe Research from “underperform” to “peer perform”.
- 8/24/2026 – Moderna had its price target raised by Barclays PLC from $48.00 to $125.00. They now have an “equal weight” rating on the stock.
- 8/21/2026 – Moderna had its price target raised by JPMorgan Chase & Co. from $40.00 to $77.00. They now have an “underweight” rating on the stock.
- 8/20/2026 – Moderna had its price target raised by UBS Group AG from $50.00 to $150.00. They now have a “neutral” rating on the stock.
- 8/20/2026 – Moderna had its price target raised by Piper Sandler from $77.00 to $167.00. They now have an “overweight” rating on the stock.
- 8/20/2026 – Moderna had its price target raised by Morgan Stanley from $39.00 to $89.00. They now have an “equal weight” rating on the stock.
- 8/19/2026 – Moderna had its “neutral” rating reaffirmed by Morgan Stanley.
- 8/19/2026 – Moderna had its price target raised by The Goldman Sachs Group, Inc. from $67.00 to $120.00. They now have a “neutral” rating on the stock.
- 8/19/2026 – Moderna had its “sector perform” rating reaffirmed by Royal Bank Of Canada. They now have a $130.00 price target on the stock.
- 8/19/2026 – Moderna was given a new $135.00 price target by Loop Capital.
- 8/19/2026 – Moderna had its “buy” rating reaffirmed by Brookline Capital Markets.
- 8/19/2026 – Moderna had its “hold” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $150.00 price target on the stock, up from $60.00.
- 8/19/2026 – Moderna was upgraded by Bank of America Corporation from “underperform” to “neutral”. They now have a $170.00 price target on the stock, up from $40.00.
- 8/19/2026 – Moderna was upgraded by William Blair from “market perform” to “outperform”.
Insider Buying and Selling
In other Moderna news, insider Shannon Klinger sold 3,471 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total value of $485,766.45. Following the transaction, the insider directly owned 74,129 shares of the company’s stock, valued at $10,374,353.55. This trade represents a 4.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Jamey Mock sold 34,836 shares of the firm’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $134.49, for a total value of $4,685,093.64. Following the completion of the transaction, the chief financial officer directly owned 59,375 shares in the company, valued at $7,985,343.75. This trade represents a 36.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 118,882 shares of company stock valued at $16,862,280. Company insiders own 10.80% of the company’s stock.
Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.
See Also
- Five stocks we like better than Moderna
- Tesla Wants to Make Its Own Chips—What Could Go Wrong?
- IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver?
- PBF Energy’s Stunning Rally Faces a Critical Test
- Citi Stock Falls Despite Earnings Beat: What Investors Need to Know
Receive News & Ratings for Moderna Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna Inc and related companies with MarketBeat.com's FREE daily email newsletter.
